GlassScriptPhysician profile
Kellie Lynn Cox
NPI 1417238981
$4,209.15
in general payments reported to CMS, 2019-2025
21 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.75 · 2022: $618 · 2023: $1,171 · 2024: $1,342 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,522.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $613.35 | 2022-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $543.41 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $543.20 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $467.08 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $395.98 | 2023-2025 | Auvelity |
| Lundbeck LLC | $372.48 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Tris Pharma INC | $237.57 | 2023-2025 | Dyanavel Xr |
| Abbvie INC. | $236.99 | 2022-2025 | |
| Alkermes, INC. | $194.36 | 2022-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $170.56 | 2023-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $90.29 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Idorsia Pharmaceuticals US INC | $83.20 | 2022-2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $58.79 | 2024-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $43.74 | 2022-2023 | Trintellix |
| Bausch Health US, LLC | $35.22 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $33.68 | 2021-2022 | |
| Sobi, INC | $26.08 | 2021 | |
| Corium, LLC | $22.64 | 2022 | |
| Ironshore Pharmaceuticals INC. | $14.35 | 2022 | |
| Merck Sharp & Dohme LLC | $13.58 | 2023 | Belsomra |
| Sanofi Pasteur INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.